ARTICLE SUMMARY:
The sale of Ellipse Technologies to NuVasive in February for a whopping multiple demonstrated that an ultra-niche market can be attractive for a start-up. As for NuVasive, the deal offered a de-risked innovation in a tricky area of spine surgery, but implementing the company’s grand ambitions for its new asset poses challenges.
NuVasive Inc.’s acquisition of Ellipse Technologies in February for $380 million plus $30 million in sales milestones, casts a spotlight on an exceptionally intriguing, albeit ultra-niche, clinical need.
